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Editorial
I
n an essay published in this 
month’s PLoS Medicine, Nicholas 
White and colleagues [1] lament 
that an insufficient understanding 
of even well-established drugs has 
led to a lack of effective treatments 
in pregnancy. They conclude that 
“we do not know how best to treat 
most tropical infectious diseases in 
pregnancy”—an alarming and shameful 
situation—and lay out causes of this 
ignorance. For example, concern 
about teratogenicity has led to the 
exclusion of pregnant women from 
clinical trials regardless of their stage of 
pregnancy, resulting in a crucial lack of 
evidence even in late pregnancy, when 
teratogenicity is not a concern. Gaps in 
the evidence on pharmacokinetics of 
some antimalarial drugs have often led 
to under-dosing of pregnant women, 
and in some cases the erroneous 
conclusion that such drugs are not 
effective in pregnancy. The authors 
note that “‘better safe than sorry’ is 
the mantra of our risk-averse age.” But 
since severe malaria has a mortality 
approaching 50% in late pregnancy, 
we concur with the authors that this 
mantra has actually produced harm.
But if the situation is bad for tropical 
diseases in pregnancy, the lack of new 
therapies can only be considered dire 
for diseases that result from pregnancy 
itself. In a policy paper published in 
January of this year, Nicholas Fisk and 
Rifat Atun [2] concluded that “the 
market has failed pregnant women.” 
Their analysis of the drug pipeline 
for obstetric disease between 1980 
and 2007 found just 17 new drugs 
undergoing evaluation between the 
preclinical and preregistration phases. 
This number compares with 660 new 
drugs for cardiovascular diseases and 
34 for amyotrophic lateral sclerosis—a 
rare disease affecting two to five per 
100,000 people. Even worse, of these 17 
obstetric drugs, only one represents a 
new class of drug. 
Further, many maternal deaths 
are due to potentially avoidable non-
obstetric causes, as highlighted by 
Clara Menéndez and colleagues, who 
analyzed deaths from a tertiary hospital 
in Mozambique [3] and found that 
infectious diseases accounted for at 
least half of all maternal deaths, “even 
though effective treatment is available 
for the four leading causes, HIV/AIDS, 
pyogenic bronchopneumonia, severe 
malaria, and pyogenic meningitis.” For 
surgical treatments that are known to 
be effective for obstetric complications, 
another PLoS Medicine article this 
month [4] argues that “the lack of basic 
surgical supplies and equipment limits 
the delivery of surgical services” in sub-
Saharan Africa, for obstetrics as well as 
for other surgical conditions.
In developed countries, with low 
rates of maternal and perinatal deaths, 
it is perhaps easy to be complacent 
about the lack of new drugs for 
pregnancy and the perinatal period, 
but globally the situation is urgent. 
According to the World Health 
Organization, there were more than 
half a million maternal deaths in 2005 
and over 6 million child deaths in the 
perinatal and neonatal periods [5]. 
Most of these deaths are in low-income 
countries—a huge, and potentially 
avoidable, loss of life. Appropriately, 
therefore, maternal and child health 
are part of the United Nations 
Millennium Development Goals, with 
specific goals between 1990 and 2015 
to reduce the under-five mortality 
rate by two-thirds and the maternal 
mortality ratio [6] by three-quarters. 
Unfortunately, 18 years into the 
program, it seems unlikely that these 
goals will be met.
No one would suggest that improving 
the health of pregnant women and 
their infants is easy. For millions 
of women, even the most basic 
determinants of maternal and child 
health are still lacking: access to basic 
health care and nutrition, autonomy 
over reproductive choices, and 
freedom from violence and poverty. 
When it comes to drug development, 
however, innovations that work for 
other areas of health care simply do not 
suffice for maternal and infant health, 
and new ways of thinking are needed. 
As Fisk and Atun argue, the current 
business model of the pharmaceutical 
industry provides no real incentive but 
rather, because of potential litigation 
in developed countries, confers strong 
disincentives to produce novel drugs 
for pregnant women. 
For pregnancy-related disorders, 
the development of drugs is perhaps 
further hindered by issues that rarely 
arise in other conditions. Although 
childbirth remains hazardous in 
all countries, there is an increasing 
expectation in developed countries that 
nowadays birth should be a “natural” 
event for both mother and child and 
that medical interventions are to be 
discouraged. Such expectations make 
doing clinical trials uniquely difficult 
when any suggestion of risk appears 
unacceptable. A qualitative study [7] 
of participants in the ORACLE trial 
of antibiotics in women presenting 
with preterm rupture of membranes, 
for example, concluded that “the 
main motivation for trial participation 
was the possibility of an improved 
outcome for the baby. The second 
and less prominent motivation was the 
opportunity to help others, but this 
was conditional on there being no risks 
associated with trial participation.” This 
expectation of no risks is unrealistic 
and was surely not what was explained 
Drug Development for Maternal Health 
Cannot Be Left to the Whims of the Market
The PLoS Medicine Editors
Citation: The PLoS Medicine Editors (2008) Drug 
development for maternal health cannot be left 
to the whims of the market. PLoS Med 5(6): e140. 
doi:10.1371/journal.pmed.0050140
Copyright: © 2008 The PLoS Medicine Editors. 
This is an open-access article distributed under 
the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, 
and reproduction in any medium, provided the 
original author and source are credited.
E-mail:  medicine_editors@plos.org
The PLoS Medicine Editors are Virginia Barbour, 
Jocalyn Clark, Larry Peiperl, Emma Veitch, Mai Wong, 
and Gavin Yamey. PLoS Medicine  |  www.plosmedicine.org 0842 June 2008  |  Volume 5  |  Issue 6  |  e140
to the participants; nevertheless, it was 
what the women themselves believed 
and expected. So while women in 
less developed countries urgently 
need more effective interventions 
in pregnancy, it may be increasingly 
difficult to test such drugs in ways that 
are acceptable to pregnant women, 
at least in the developed world. The 
market-driven pharmaceutical model 
has little incentive to resolve the conflict 
of providing the safety that women 
expect from trials, while at the same 
time accepting liability and providing 
compensation in cases when testing 
does, as it inevitably will, cause harm.
What’s the answer then? The issue 
of the market failing to develop 
necessary drugs is of course not a 
new one. In 2004, Tim Hubbard and 
James Love [8] argued that reliance 
on intellectual property rights to 
finance research and development 
in the pharmaceutical industry was 
both driving up drug prices and 
hindering essential drug development. 
Recognizing this hindrance, in 2003 
five public sector organizations teamed 
up with Médecins Sans Frontières and 
the Special Programme for Research 
and Training in Tropical Diseases 
to launch the Drugs for Neglected 
Diseases Initiative (DNDI; http://www.
dndi.org/). This drug development 
project does not prioritize maximum 
profitability over medical need. Instead 
it adopts a “needs-driven” portfolio-
based approach that facilitates basic 
science, preclinical, and clinical 
research on targeted diseases. Fisk 
and Atun present ways in which such 
“push” and “pull” mechanisms can 
provide solutions. An example of a 
push mechanism is DNDI’s dedicated 
financial support to research networks 
for developing drugs for specific 
indications; pull mechanisms include 
an advanced market commitment 
aimed at creating a market for a 
future drug. These mechanisms have 
been successfully applied thus far 
for malaria, AIDS, tuberculosis, and 
neglected tropical diseases and might 
be applied to maternal health. 
Fisk and Atun go on to urge that 
not-for-profit options be carefully 
explored and suggest that new 
initiatives be put in place to encourage 
the testing and collection of data on 
old and new drugs, especially for the 
most life-threatening conditions in 
pregnancy. One such mechanism is 
noted by White and colleagues and 
involves the systematic collection 
of data via pregnancy registries; an 
essential but expensive long-term 
investment that would, like other 
long-term initiatives, be unlikely to 
find support in the current business 
environment of the pharmaceutical 
industry. A key part of any mechanism 
would be the need to specifically 
accept liability when harm occurs. 
And, as an aside, the publishing 
industry has a part to play too. It is 
essential that the results, especially 
harms, generated by these initiatives 
be made widely available. Open access 
to all such data is not a luxury, and 
should be ensured by publishers. 
The time has come to accept that 
the development of drugs for maternal 
health cannot be constrained by 
market-driven needs. There is no lack 
of ideas for addressing this issue; what’s 
needed is political will.
References
1.  White NJ, McGready RM, Nosten FH (2008) 
New medicines for tropical diseases in 
pregnancy: Catch-22. PLoS Med 5: e133. 
doi:10.1371/journal.pmed.0050133
2.  Fisk NM, Atun R (2008) Market failure and the 
poverty of new drugs in maternal health. PLoS 
Med 5: e22.doi:10.1371/journal.pmed.0050022 
3.  Menéndez C, Romagosa C, Ismail MR, Carrilho 
C, Saute F, et al. (2008) An autopsy study 
of maternal mortality in Mozambique: The 
contribution of infectious diseases. PLoS Med 
5: e44. doi:10.1371/journal.pmed.0050044
4.  Ozgediz D, Riviello R (2008) The “other” 
neglected diseases in global public health: 
Surgical conditions in sub-Saharan Africa. 
PLoS Med 5: e121. doi:10.1371/journal.
pmed.0050121
5.  World Health Organization (2007) Maternal 
mortality in 2005: Estimates developed by 
WHO, UNICEF, UNFPA and The World 
Bank. Available: http://www.who.int/
reproductivehealth/publications/maternal_
mortality_2005/mme_2005.pdf. Accessed 22 
May 2008.
6. United Nations (2008) The UN Millennium 
Development Goals. Available: http://www.
un.org/millenniumgoals/. Accessed 22 May 
2008.
7.  Kenyon S, Dixon-Woods M, Jackson CJ, 
Windridge K, Pitchforth E (2006) Participating 
in a trial in a critical situation: A qualitative 
study in pregnancy. Qual Saf Health Care 15: 
98-101. doi:10.1136/qshc.2005.015636
8.  Hubbard T, Love J (2004) A new trade 
framework for global healthcare R&D. PLoS 
Biol 2: e52. doi:10.1371/journal.pbio.0020052